Mechanism of death in heart failure: The vasodilator-heart failure trials

Steven Goldman, Gary Johnson, Jay N. Cohn, Guillermo Cintron, Raphael Smith, Gary Francis

Research output: Contribution to journalArticle

142 Citations (Scopus)

Abstract

Background. The Vasodilator-Heart Failure Trial (V-HeFT) data base provides information on the mechanism of death of male veterans entered into two trials that evaluated the effect of vasodilator therapy on survival in heart failure. Methods and Results. Men aged 18-75 years with heart failure were recruited at 13 Department of Veterans Affairs Medical Centers. In V-HeFT I, 283 of 642 patients (44%) died during follow-up (average, 2.3 years), and in V-HeFT II, 285 of 804 randomized patients (35.5%) died during follow-up (average, 2.5 years). Mechanism of death was established centrally using a standardized classification. In V-HeFT I, 124 of the 283 deaths (43.8%) were sudden with no worsening of symptoms; in V-HeFT II, 104 of the 285 deaths (36.5%) were sudden. An average of 31.5% of the deaths (31.4% and 31.6%, respectively) in the two trials was due to pump failure. The proportion of sudden deaths that occurred without worsening of symptoms was similar in patients with and without ischemic heart failure. Sudden deaths tended to occur earlier and pump failure deaths later in both V-HeFT studies. There was a trend for a lower percentage of cardiac deaths from pump failure and a higher percentage from sudden death in subgroups with higher peak exercise oxygen consumption (V̇o2), higher ejection fraction, and lower plasma norepinephrine levels. The proportion of deaths that occurred suddenly was similar in placebo, prazosin, and hydralazine plus isosorbide dinitrate treatment groups but was significantly lower in the enalapril treatment group. In V-HeFT I, measures of cardiac function and V̇o2 predicted pump failure death and sudden death. In V-HeFT II, V̇o2 and cardiothoracic ratio were independent predictors of all-cause deaths and pump failure deaths; only ejection fraction was an independent predictor of both pump failure and sudden death. Conclusion. Although mechanistically distinct terminal events can be identified in patients with heart failure and physiological measurements can provide some insight into the risk of these disparate events, sudden death and pump failure death both appear largely to be linked to the severity of cardiac dysfunction and symptoms. Strategies to identify individuals for selective preventive therapy are not yet practical.

Original languageEnglish (US)
JournalCirculation
Volume87
Issue number6 SUPPL. 1
StatePublished - Jun 1993

Fingerprint

Vasodilator Agents
Heart Failure
Sudden Death
Veterans
Isosorbide Dinitrate
Hydralazine
Enalapril
Prazosin
Therapeutics
Oxygen Consumption
Cause of Death
Norepinephrine
Placebos
Databases
Exercise

Keywords

  • Clinical trials
  • Heart failure
  • Morbidity
  • Mortality
  • Sudden death

Cite this

Goldman, S., Johnson, G., Cohn, J. N., Cintron, G., Smith, R., & Francis, G. (1993). Mechanism of death in heart failure: The vasodilator-heart failure trials. Circulation, 87(6 SUPPL. 1).

Mechanism of death in heart failure : The vasodilator-heart failure trials. / Goldman, Steven; Johnson, Gary; Cohn, Jay N.; Cintron, Guillermo; Smith, Raphael; Francis, Gary.

In: Circulation, Vol. 87, No. 6 SUPPL. 1, 06.1993.

Research output: Contribution to journalArticle

Goldman, S, Johnson, G, Cohn, JN, Cintron, G, Smith, R & Francis, G 1993, 'Mechanism of death in heart failure: The vasodilator-heart failure trials', Circulation, vol. 87, no. 6 SUPPL. 1.
Goldman S, Johnson G, Cohn JN, Cintron G, Smith R, Francis G. Mechanism of death in heart failure: The vasodilator-heart failure trials. Circulation. 1993 Jun;87(6 SUPPL. 1).
Goldman, Steven ; Johnson, Gary ; Cohn, Jay N. ; Cintron, Guillermo ; Smith, Raphael ; Francis, Gary. / Mechanism of death in heart failure : The vasodilator-heart failure trials. In: Circulation. 1993 ; Vol. 87, No. 6 SUPPL. 1.
@article{d4c9ce4449164303bc32bf081964efcc,
title = "Mechanism of death in heart failure: The vasodilator-heart failure trials",
abstract = "Background. The Vasodilator-Heart Failure Trial (V-HeFT) data base provides information on the mechanism of death of male veterans entered into two trials that evaluated the effect of vasodilator therapy on survival in heart failure. Methods and Results. Men aged 18-75 years with heart failure were recruited at 13 Department of Veterans Affairs Medical Centers. In V-HeFT I, 283 of 642 patients (44{\%}) died during follow-up (average, 2.3 years), and in V-HeFT II, 285 of 804 randomized patients (35.5{\%}) died during follow-up (average, 2.5 years). Mechanism of death was established centrally using a standardized classification. In V-HeFT I, 124 of the 283 deaths (43.8{\%}) were sudden with no worsening of symptoms; in V-HeFT II, 104 of the 285 deaths (36.5{\%}) were sudden. An average of 31.5{\%} of the deaths (31.4{\%} and 31.6{\%}, respectively) in the two trials was due to pump failure. The proportion of sudden deaths that occurred without worsening of symptoms was similar in patients with and without ischemic heart failure. Sudden deaths tended to occur earlier and pump failure deaths later in both V-HeFT studies. There was a trend for a lower percentage of cardiac deaths from pump failure and a higher percentage from sudden death in subgroups with higher peak exercise oxygen consumption (V̇o2), higher ejection fraction, and lower plasma norepinephrine levels. The proportion of deaths that occurred suddenly was similar in placebo, prazosin, and hydralazine plus isosorbide dinitrate treatment groups but was significantly lower in the enalapril treatment group. In V-HeFT I, measures of cardiac function and V̇o2 predicted pump failure death and sudden death. In V-HeFT II, V̇o2 and cardiothoracic ratio were independent predictors of all-cause deaths and pump failure deaths; only ejection fraction was an independent predictor of both pump failure and sudden death. Conclusion. Although mechanistically distinct terminal events can be identified in patients with heart failure and physiological measurements can provide some insight into the risk of these disparate events, sudden death and pump failure death both appear largely to be linked to the severity of cardiac dysfunction and symptoms. Strategies to identify individuals for selective preventive therapy are not yet practical.",
keywords = "Clinical trials, Heart failure, Morbidity, Mortality, Sudden death",
author = "Steven Goldman and Gary Johnson and Cohn, {Jay N.} and Guillermo Cintron and Raphael Smith and Gary Francis",
year = "1993",
month = "6",
language = "English (US)",
volume = "87",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "6 SUPPL. 1",

}

TY - JOUR

T1 - Mechanism of death in heart failure

T2 - The vasodilator-heart failure trials

AU - Goldman, Steven

AU - Johnson, Gary

AU - Cohn, Jay N.

AU - Cintron, Guillermo

AU - Smith, Raphael

AU - Francis, Gary

PY - 1993/6

Y1 - 1993/6

N2 - Background. The Vasodilator-Heart Failure Trial (V-HeFT) data base provides information on the mechanism of death of male veterans entered into two trials that evaluated the effect of vasodilator therapy on survival in heart failure. Methods and Results. Men aged 18-75 years with heart failure were recruited at 13 Department of Veterans Affairs Medical Centers. In V-HeFT I, 283 of 642 patients (44%) died during follow-up (average, 2.3 years), and in V-HeFT II, 285 of 804 randomized patients (35.5%) died during follow-up (average, 2.5 years). Mechanism of death was established centrally using a standardized classification. In V-HeFT I, 124 of the 283 deaths (43.8%) were sudden with no worsening of symptoms; in V-HeFT II, 104 of the 285 deaths (36.5%) were sudden. An average of 31.5% of the deaths (31.4% and 31.6%, respectively) in the two trials was due to pump failure. The proportion of sudden deaths that occurred without worsening of symptoms was similar in patients with and without ischemic heart failure. Sudden deaths tended to occur earlier and pump failure deaths later in both V-HeFT studies. There was a trend for a lower percentage of cardiac deaths from pump failure and a higher percentage from sudden death in subgroups with higher peak exercise oxygen consumption (V̇o2), higher ejection fraction, and lower plasma norepinephrine levels. The proportion of deaths that occurred suddenly was similar in placebo, prazosin, and hydralazine plus isosorbide dinitrate treatment groups but was significantly lower in the enalapril treatment group. In V-HeFT I, measures of cardiac function and V̇o2 predicted pump failure death and sudden death. In V-HeFT II, V̇o2 and cardiothoracic ratio were independent predictors of all-cause deaths and pump failure deaths; only ejection fraction was an independent predictor of both pump failure and sudden death. Conclusion. Although mechanistically distinct terminal events can be identified in patients with heart failure and physiological measurements can provide some insight into the risk of these disparate events, sudden death and pump failure death both appear largely to be linked to the severity of cardiac dysfunction and symptoms. Strategies to identify individuals for selective preventive therapy are not yet practical.

AB - Background. The Vasodilator-Heart Failure Trial (V-HeFT) data base provides information on the mechanism of death of male veterans entered into two trials that evaluated the effect of vasodilator therapy on survival in heart failure. Methods and Results. Men aged 18-75 years with heart failure were recruited at 13 Department of Veterans Affairs Medical Centers. In V-HeFT I, 283 of 642 patients (44%) died during follow-up (average, 2.3 years), and in V-HeFT II, 285 of 804 randomized patients (35.5%) died during follow-up (average, 2.5 years). Mechanism of death was established centrally using a standardized classification. In V-HeFT I, 124 of the 283 deaths (43.8%) were sudden with no worsening of symptoms; in V-HeFT II, 104 of the 285 deaths (36.5%) were sudden. An average of 31.5% of the deaths (31.4% and 31.6%, respectively) in the two trials was due to pump failure. The proportion of sudden deaths that occurred without worsening of symptoms was similar in patients with and without ischemic heart failure. Sudden deaths tended to occur earlier and pump failure deaths later in both V-HeFT studies. There was a trend for a lower percentage of cardiac deaths from pump failure and a higher percentage from sudden death in subgroups with higher peak exercise oxygen consumption (V̇o2), higher ejection fraction, and lower plasma norepinephrine levels. The proportion of deaths that occurred suddenly was similar in placebo, prazosin, and hydralazine plus isosorbide dinitrate treatment groups but was significantly lower in the enalapril treatment group. In V-HeFT I, measures of cardiac function and V̇o2 predicted pump failure death and sudden death. In V-HeFT II, V̇o2 and cardiothoracic ratio were independent predictors of all-cause deaths and pump failure deaths; only ejection fraction was an independent predictor of both pump failure and sudden death. Conclusion. Although mechanistically distinct terminal events can be identified in patients with heart failure and physiological measurements can provide some insight into the risk of these disparate events, sudden death and pump failure death both appear largely to be linked to the severity of cardiac dysfunction and symptoms. Strategies to identify individuals for selective preventive therapy are not yet practical.

KW - Clinical trials

KW - Heart failure

KW - Morbidity

KW - Mortality

KW - Sudden death

UR - http://www.scopus.com/inward/record.url?scp=0344691646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344691646&partnerID=8YFLogxK

M3 - Article

C2 - 8500236

AN - SCOPUS:0027262357

VL - 87

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 6 SUPPL. 1

ER -